Form 4: Helius Medical Technologies Director Paul Buckman Granted Stock Options

Director Paul Buckman received stock options for 31,000 shares of Helius Medical Technologies, Inc. (HSDT) on July 2, 2024.

Summary

• Paul Buckman, a director of Helius Medical Technologies, Inc. (HSDT), was granted stock options on July 2, 2024.
• The options are for 31,000 shares of Class A Common Stock.
• The exercise price of the options is $0.965 per share.
• The options vest in four equal quarterly installments starting September 30, 2024, contingent upon continued service.
• The options expire on July 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences routinely use stock options to incentivize their directors and officers.
• The vesting schedule of four quarterly installments is also a common practice, ensuring continued service and commitment.

Key Dates

Keywords

stock options, director, Helius Medical Technologies, HSDT, equity incentive plan, beneficial ownership